Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy

NCT01811212 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01811212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01811212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2013
Completion date
October 9, 2017
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

poorly differentiated thyroid gland carcinoma, recurrent thyroid gland carcinoma, stage i thyroid gland follicular carcinoma, stage i thyroid gland papillary carcinoma, stage ii thyroid gland follicular carcinoma, stage ii thyroid gland papillary carcinoma, stage iii thyroid gland follicular carcinoma, stage iii thyroid gland papillary carcinoma, stage iva thyroid gland follicular carcinoma, stage iva thyroid gland papillary carcinoma, stage ivb thyroid gland follicular carcinoma, stage ivb thyroid gland papillary carcinoma, stage ivc thyroid gland follicular carcinoma, stage ivc thyroid gland papillary carcinoma, tall cell variant thyroid gland papillary carcinoma, thyroid gland oncocytic follicular carcinoma